Dyadic International to Announce Year End 2017 Financial Results and Host Conference Call on Tuesday March 27, 2018
March 13 2018 - 4:30PM
JUPITER, Fla., March 13, 2018 (GLOBE NEWSWIRE)
-- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 expression system to help speed up the development
and production of biologic vaccines and drugs at flexible
commercial scales, announced today that it will report its
financial results for the year ended December 31, 2017 after the
market close on Tuesday, March 27, 2018 and that it will host a
conference call that day at 5:00 p.m. Eastern Time to discuss those
results.
In order to participate in the live session,
please use the following dial-in numbers five to ten minutes prior
to the start time:
Calling from the United States or Canada: 888-437-9445
Calling from other countries: +
719-325-4857
Confirmation Code: 5790217
A replay of the conference call will be
available on Dyadic’s website (www.dyadic.com) within 24 hours
after the live event.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila,
nicknamed C1. The C1 microorganism, which enables the development
and large-scale manufacture of low cost proteins, has the potential
to be further developed into a safe and efficient expression system
that may help speed up the development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales. Dyadic is using the C1 technology and
other technologies to conduct research, development and commercial
activities for the development and manufacturing of human and
animal vaccines, monoclonal antibodies, biosimilars and/or
biobetters, and other therapeutic proteins. Additionally, the
Company has entered into a proof of concept research project to
explore the potential of its C1 technology to produce an important
active moiety for a third party. Dyadic pursues research and
development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of using these technologies in the
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic vaccines and drugs to market faster, in greater volumes,
at lower cost, and potentially with new properties to drug
developers and manufacturers and, hopefully, improve access and
cost to patients and the healthcare system, but most importantly
save lives.
Please visit Dyadic’s website at www.dyadic.com
for additional information, including details regarding Dyadic’s
plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of the
federal securities laws. These forward-looking statements involve
risks, uncertainties and other factors that could cause Dyadic’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Investors
are urged to consider these factors carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and,
except as required by law, Dyadic expressly disclaims any intent or
obligation to update or revise any forward-looking statements to
reflect actual results, any changes in expectations or any change
in events. Factors that could cause results to differ materially
include, but are not limited to: (1) general economic, political
and market conditions; (2) our ability to carry out and implement
our biopharmaceutical research and business plans and strategic
initiatives; (3) Dyadic’s ability to retain and attract employees,
consultants, directors and advisors; (4) our ability to implement
and successfully carry out Dyadic’s and third parties research and
development efforts; (5) our ability to obtain new license and
research agreements; (6) our ability to maintain our existing
access to, and/or expand access to third party contract research
organizations in order to carry out our research projects for
ourselves and third parties; (7) competitive pressures and reliance
on key third-party and related party research organizations,
customers and collaborators; and (8) other factors discussed in
Dyadic’s publicly available filings, including information set
forth under the caption “Risk Factors” in our December 31, 2016,
Annual Report filed with OTC Markets on March 24, 2017. New risks
and uncertainties arise from time to time, and it is impossible for
us to predict these events or how they may affect us.
Contact:
Dyadic International, Inc.
Ping Rawson
Director of Financial Reporting
Phone: 561-743-8333
Email prawson@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024